Benzinga | Aug 26, 2021 07:37AM EDT

Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

* Name change underscores the Company's transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseases

* Robust pipeline of six product candidates advancing in development with eight ongoing clinical programs

* Four therapies with Rare Pediatric Disease Designation with each potentially eligible for a Priority Review Voucher upon approval

* Multiple data readouts anticipated in the second half of 2021